Intraocular Lens Drug Microspheres Prevent Capsular Opacification
Solution Overview
Problem
Current intraocular lenses require postoperative administration of eye drops to prevent inflammation and infection, which can be challenging for patients, especially the elderly, and may lead to complications like posterior capsular opacification, necessitating additional surgeries or treatments.
Innovation Solution
Intraocular lenses with drug-containing microspheres attached to the haptics, using biodegradable materials like poly(L-lactic acid) and poly(lactic-co-glycolic acid), which release drugs in a controlled manner over time, reducing the need for postoperative eye drops and minimizing complications such as posterior capsular opacification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If postoperative eye drops are administered to prevent inflammation and infection, then the risk of complications is reduced, but patient compliance becomes difficult to achieve and treatment complexity increases
Solution Approach 1:
The patent applies preliminary action by incorporating drug-containing microspheres onto the intraocular lens before implantation. The microspheres are pre-loaded with therapeutic agents that will be released in situ after surgery, eliminating the need for postoperative eye drop administration and ensuring immediate drug delivery at the surgical site.
Solution Approach 2:
The intraocular lens with attached microspheres serves itself by providing continuous drug release directly at the implantation site. The lens structure itself becomes the drug delivery system, requiring no external intervention or patient compliance for administration, while maintaining reliable prevention of inflammation and infection.
2Reliability
If frequent eye drop administration is required, then therapeutic effect is maintained, but patient burden increases and quality of life decreases
Solution Approach 1:
The microspheres attached to the intraocular lens provide continuous drug release over an extended period following implantation. This continuous delivery mechanism maintains therapeutic effect without requiring repeated patient interventions, thereby reducing patient burden while ensuring reliable therapeutic outcomes.
Solution Approach 2:
The drug delivery system is prepared in advance with microspheres loaded with therapeutic agents. After a single implantation procedure, the lens automatically provides sustained drug release, eliminating the need for frequent patient-administered eye drops and significantly reducing ongoing patient burden.
3Quantity of substance
If drugs are delivered systemically or through eye drops, then treatment coverage is achieved, but drug concentration at target site is insufficient and side effects occur
Solution Approach 1:
The patent applies local quality by delivering drugs directly to the local site of implantation through microspheres attached to the intraocular lens. This localized delivery achieves high drug concentration at the target site (posterior chamber of the eye) while minimizing systemic exposure and associated side effects, as the drug is released precisely where it is needed.
Solution Approach 2:
The microspheres serve as an intermediary carrier that transports therapeutic agents directly to the target site within the eye. This intermediary delivery mechanism bypasses systemic circulation and direct eye drop application, achieving concentrated local drug delivery while reducing exposure to harmful effects in other tissues.
4Ease of manufacture
If conventional intraocular lenses are used, then surgical simplicity is maintained, but postoperative complications require additional treatments and surgeries
Solution Approach 1:
The intraocular lens is designed with multi-functionality by combining the optical function of the lens with the therapeutic function of drug delivery. The lens structure serves both as the visual implant and as a carrier for therapeutic microspheres, providing prevention of posterior capsular opacification alongside its primary optical function, without significantly complicating the surgical procedure.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The controlled release of antibiotics, anti-inflammatory, and anti-proliferative drugs from the microspheres reduces the risk of inflammation, infection, and posterior capsular opacification, improving patient outcomes by eliminating the need for frequent eye drop administration and potential additional surgeries, while ensuring targeted drug delivery without visual impairment.
Implementation Method 1
The microspheres are made from biodegradable materials like poly(L-lactic acid) and poly(lactic-co-glycolic acid), which release drugs in a controlled manner over time
Data Source
Figure 1~2
Figure 3~5
AI summary
A composition is provided comprising a first material that is selected from an acrylate, a fluorinated polymer, a polyimide, a collamer, a silicone, or a polyolefin; and a second material that is biodegradable and comprises at least one encapsulated compound. The first material is attached covalently to the second material, and the encapsulated compound is controllably released over a period of time. The biodegradable material may be a polymer. The encapsulated compound is suitably a drug. The composition may be comprised within an intraocular lens.